[Treatment of primary hyperlipoproteinemias. Comparison of N 041 with clofibrate].
The effect of essential phospholipids in combination with Clofibrate (N 041) was compared with that of Clofibrate alone in a double blind study in 96 patients with hypertriglyceridemia and/or hypercholesterolemia. The serum triglycerides fell more markedly with N 041 than with Clofibrate therapy alone. The greater cholesterol-lowering effect of N 041 was significant after treatment lasting 3 weeks and just failed to reach the 5% significance level after 6 weeks. Both preparations were well tolerated.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D005997:Glycerylphosphorylcholine / Q000627:therapeutic use*; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy; D006949:Hyperlipidemias / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D002914:Chylomicrons; D004338:Drug Combinations; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010713:Phosphatidylcholines; D014280:Triglycerides; D005997:Glycerylphosphorylcholine; D002784:Cholesterol; D002994:Clofibrate
Behandlung primärer Hyperlipoproteinämien. N 041 im Wirkungsvergleich zu Clofibrat